Abstract: A database management engine provides a user interface that allows users to access and modify employee information in a database. The database includes entries for employees, and each database entry includes identifying information about the associated employee. A user can request to modify data within database entries, for instance in order to update information associated with an employee. Responsive to the request, the database management engine identifies liabilities associated with the database modification stemming from associated tax laws. Based on the identified tax liabilities, the engine computes the aggregate tax liability owed by the employer and/or employee. Before modifying a database entry, the engine modifies the user interface to include interface elements detailing the computed aggregate tax liability. The user explicitly can be required to confirm the database modification in view of the aggregate tax liability.

Abstract: Apparatus and methods are disclosed for implementing a copilot as a network of microservices including specialized large language models (LLMs) or other trained machine learning (ML) tools. The microservice network architecture supports flexible, customizable, or dynamically determinable dataflow. Compared to much larger competing LLMs, comparable or superior performance is achieved for certain tasks, while significantly reducing hardware requirements and computation time. Disclosed examples incorporate microservices for expansion, retrieval, embedding, and evaluation, in addition to one or more core microservices. Optionally, intermodal I/O, multiple data repositories, competency qualification, or human feedback can be supported. Multiple core microservices can support varying client authorizations or cognitive functions. The disclosed architecture supports any major LLM use case and can be deployed on a single compute node with a single GPU.

Abstract: This disclosure relates to an improved chemical process for making compounds which are CIC-1 chloride channel inhibitors.

Abstract: The present disclosure relates to compounds of Formula I: suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.

Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.

Abstract: The present disclosure relates to compounds of Formula I: suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.

Abstract: This disclosure relates to an improved chemical process for making compounds which are CIC-1 chloride channel inhibitors.

Abstract: Disclosed is a computer based method for securing a financial transaction. A transaction device does not include any human readable data that can be used to identify the account owner and/or the transaction account. A first code and a second code are combined to determine an alias transaction account code. A transaction account is determined based upon the alias transaction account code.

Abstract: Disclosed is a computer based method for securing a financial transaction. A transaction device does not include any human readable data that can be used to identify the account owner and/or the transaction account. A first code and a second code are combined to determine an alias transaction account code. A transaction account is determined based upon the alias transaction account code.

Abstract: This disclosure includes a system, method, and article of manufacture for securely processing a transaction. The method may comprise performing a three factor authentication, communicating and/or generating, to a web client, a token in response to a transaction request and based upon the three factor authentication, comparing the token to a received token, and authorizing the transaction request based upon the comparing. Three factor authentication may comprise authenticating a web client to a transaction account associated with an individual, authenticating a web client to a payment network associated with the transaction account, and authenticating an individual to the transaction account based upon a biometric sample.

Abstract: Disclosed is a computer based method including receiving a request, by a virtual mobile transaction computer, from a user device or from an application running on the user device. The user and the user device are verified and authenticated based on one or more parameters. A transaction account is determined, where the transaction account is associated with the user. A barcode is sent to the user device and the barcode is used to initiate a payment for a purchase transaction associated with the request.

Abstract: Disclosed is a computer based method including receiving a request, by a virtual mobile transaction computer, from a user device or from an application running on the user device. The user and the user device are verified and authenticated based on one or more parameters. A transaction account is determined, where the transaction account is associated with the user. A barcode is sent to the user device and the barcode is used to initiate a payment for a purchase transaction associated with the request.

Abstract: Disclosed is a computer based method for securing a financial transaction. A transaction device does not include any human readable data that can be used to identify the account owner and/or the transaction account. A first code and a second code are combined to determine an alias transaction account code. A transaction account is determined based upon the alias transaction account code.

Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.

Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.

Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.

Abstract: The present invention relates to the composition of compounds having the generic structure: and to a method of treatment or prevention of pain using the above compounds.

Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.

Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.

Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.